PDCD1 and acute myeloid leukemia: To explore the resistance mechanisms of checkpoint blockade therapy, two studies combined single-cell TCR sequencing, immune profiling, scRNA-seq, and CITE-seq on AML patients treated with the combination of hypomethylating agents and PD-1 inhibitor [38, 114].